2012 Fiscal Year Final Research Report
Establishment of novel therapy for hepatitis C by double DDS drugs
| Project/Area Number |
22500410
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Biomedical engineering/Biological material science
|
|---|
| Research Institution | Nihon University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Keywords | ナノバイオロジー / ナノメディスン |
|---|
| Research Abstract |
Novel drug carrier for ribavirin was developed for treatment of chronic hepatitis C. Polymeric nanoparticles encapsulating ribavirin were prepared fromarabinogalactan-poly(L-lysine) conjugates and poly(lactic acid). Ribavirin was specifically accumulated in the liver of mice and the amount of ribavirin was gradually decreased. Thus, it is expected that the nanoparticles are useful for treatment of chronic hepatitis C.
|
-
-
-
-
-
-
-
-
-
[Journal Article] Therapeutic effect of lecithinized superoxide dismutase (PC-SOD) on bleomycin-induced pulmonary fibrosis.2010
Author(s)
Tanaka KI., Ishihara T., Azuma A., Kudoh S., Ebina M., Nukiwa T., Sugiyama Y., Tasaka Y., Namba T., Ishihara T., Sato K., Mizushima Y., Mizushima T.
-
Journal Title
Am J Physiol Lung Cell Mol Physiol.
Volume: 298
Pages: L348-60
Peer Reviewed
-
-
-
-
-
-
-
-
-
